The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification
Year: 2015
Type: review
Abstract: Mass spectrometry (MS) -based proteomics has become an indispensable tool with broad applications in systems biology and biomedical research. With recent advances in liquid chromatography (LC) and MS instrumentation, LC-MS is making increasingly significant contributions to clinical applications, especially in the area of cancer biomarker discovery and verification. To overcome challenges associated with analyses of clinical samples (for example, a wide dynamic range of protein concentrations in bodily fluids and the need to perform high throughput and accurate quantification of candidate biomarker proteins), significant efforts have been devoted to improve the overall performance of LC-MS-based clinical proteomics platforms. Reviewed here are the recent advances in LC-MS and its applications in cancer biomarker discovery and quantification, along with the potentials, limitations and future perspectives.
Source: Expert Review of Proteomics
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: green
Awards: G1895886590, Regulatory Networks and Biomarkers of Beta-cell Dysfunction and Apoptosis, G5665985566, A Research Resource for Ultra-sensitive High Throughput Proteomics, Center for Application of Advanced Clinical Proteomic Technologies for Cancer, A Universal Multiplex Assay System for High-Throughput Clinical Applications
OpenAlex ID: W2180723850
